Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Engine and Congruent Ventures have both participated in a series A round for the developer of high-voltage superconducting transmission lines.

UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.

BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Exploiting UChicago research, Reflexion is eyeing an expansion in Asia after receiving $40m in additional series D funding to bring the round to $150m.

OneTrust has acquired DocuVision, providing exits to investors including Berkeley SkyDeck Fund and Oxford Seed Fund.

Acorn Bioventures has led a series B round for the cancer-focused biopharmaceutical spinout of CU Boulder.

AbbVie has bought an exclusive option to acquire Mitokinin once the UCSF spinout completes IND-enabling studies for its Parkinson’s treatment.